The US Food and Drug Administration's Center for Biologics Evaluation and Research (CBER) is again extending an invitation to biologics facilities for participation in its Regulatory Site Visit ...
Cell and gene therapy manufacturers may not like the idea of spending more money on US Food and Drug Administration (FDA) reviewers, but a top official said if a new pilot project goes according to ...
Facilitating product development, conducting research, boosting preparedness against health threats and organizational excellence top the US Food and Drug Administration’s (FDA) Center for Biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results